Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOA | P61586 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 10/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 10/20 | 0.39 |
| ▸ | WNT1 | P04628 | 9/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | IDH2 | P48735 | 2/20 | 0.35 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16238636 | 0.96 | RHOA (0.40) | RHOAGSK3BDYRK1AWNT1CA2 | |
| SCHEMBL17624504 | 0.92 | RHOA (0.43) | RHOAGSK3BDYRK1AWNT1CA2 | |
| SCHEMBL16249975 | 0.90 | RHOA (0.48) | RHOACA2CA9BRAFIDH2 | |
| SCHEMBL16249976 | 0.90 | RHOA (0.39) | RHOAGSK3BDYRK1AWNT1CA2 | |
| SCHEMBL19699090 | 0.89 | DYRK1A (0.42) | GSK3BDYRK1AWNT1CA9BRAF | |
| SCHEMBL19365674 | 0.89 | RHOA (0.43) | RHOACA2CA9BRAFIDH2 | |
| SCHEMBL19706100 | 0.88 | DYRK1A (0.39) | GSK3BDYRK1AWNT1BRAF | |
| SCHEMBL17618812 | 0.88 | RHOA (0.39) | RHOAGSK3BDYRK1AWNT1CA2 | |
| SCHEMBL19865030 | 0.86 | DYRK1A (0.40) | RHOAGSK3BDYRK1AWNT1CA2 | |
| SCHEMBL16776205 | 0.86 | TSHR (0.46) | CA2CA9KMORPS6KB1IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | RHOA 4858/4885GSK3B 2465/4885DYRK1A 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.